September 29th - 2011
Recently published paper in Eur Urol
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M, Eardley I, Giuliano F, Hatzichristou D, Kaplan SA, Maggi M, McVary KT, Mirone V, Porst H, Roehrborn CG.
Eur Urol. 2011 Oct;60(4):809-25.
September 29th - 2011
Bio-Europe in Düsseldorf, October-November 2011
Pelvipharm will be represented by Delphine Behr-Roussel at the next Bio-Europe meeting in Düsseldorf, October 31 - November 2, 2011. We warmly invite you to take this opportunity to learn more about our services.
If you’d like to set up a specific meeting at any time throughout the conference, please email staffpelvipharm@pelvipharm.com and we will be happy to assist you.
September 29th - 2011
Recently published paper in Int J Clin Pract
Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events.
Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I.
Int J Clin Pract. 2011 Sep;65(9):1005-13.
September 26th - 2011
Recently published paper in Eur Urol
Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence.
Martínez-Salamanca JI, Carballido J, Eardley I, Giuliano F, Gratzke C, Rosen R, Salonia A, Stief C.
Eur Urol. 2011 Sep; 60(3):527-35.
September 15th - 2011
Recent paper highlighted in Eur Urol editorial
Recently accepted paper in European Urology (Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: A proof of concept study for the treatment of PDE5 inhibitor failure. Oudot A., Behr-Roussel D., Poirier S., Sandner P., Bernabé J., Alexandre L., Giuliano F. (Eur. Urol. Available online July 30th 2011, in press) is published as a Platinium Priority and highlighted by an editorial written by an expert in this field, Pr V. Mirone.
Pr V. Mirone stated in this editorial that “the animal model used in this study perfectly represents the type of lesion that usually occurs during a nerve-sparing radical prostatectomy procedure” and that the results “completely concur with the partial clinical response to PDE5 inhibitors routinely observed in patients who underwent a nerve-sparing radical prostatectomy”. The novelty of this study is also emphasized: “The results of the study by Oudot et al. no doubt point us in the right direction to manage ED difficult patients more effectively” (Eur. Urol. Available online August 16th 2011).
August 31st - 2011
Recently published paper in BJU Int
Effects of potassium channel modulators on myogenic spontaneous phasic contractile activity in human detrusor from neurogenic patients.
Oger S, Behr-Roussel D, Gorny D, Bernabé J, Comperat E, Chartier-Kastler E, Denys P, Giuliano F.
BJU Int - (2011 Aug) : 108(4):604-11
July 26th - 2011
Recently accepted paper in Eur Urol as platinium priority
Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: A proof of concept study for the treatment of PDE5 inhibitor failure.
Oudot A., Behr-Roussel D., Poirier S., Sandner P., Bernabé J., Alexandre L., Giuliano F.
Eur. Urol. - 2011 Nov : 60(5):1020-1026.
June 29th - 2011
AUA education and research, Inc. congratulates Delphine Behr-Roussel
American urological association education and research, Inc. congratulates Delphine Behr-Roussel for her presentation at AUA 2011 in Washington, DC, USA, 14 -19 may 2011.
The abstract “A new Experimental Rat Model of Erectile Dysfunction and Lower Urinary Tract Symptoms Associated with Benign Prostate Hyperplasia: The Testosterone-supplemented Spontaneously Hypertensive Rat” was selected to be presented as a part of an overall scientific lecture on BPH at the 2011 Best of AUA/JUA Annual Meeting to be held in Tokyo, Japan, October 1-2, 2011.
This abstract will be presented by Dr. Yoshiyuki Kojima to young Japanese residents.
May 30th - 2011
Recently accepted paper in Curr Opin Urol
Botulinum neurotoxin A for male lower urinary tract symptoms.
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F.
Curr Opin Urol. 2011 Jan;21(1):13-21. Review.
(Erratum in: Curr Opin Urol. 2011 May;21(3):265. Dosage error in article text.)
May 24th - 2011
Take Home Message on “Sexual function and dysfunction” session - AUA 2011
Pelvipharm is quoted in the “Take Home Messages” on “Sexual function and dysfunction” presented by Gerald Brock at the AUA (American Urological Association) in Washington, DC the may 17th, 2011.
Pelvipharm’s study “Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil might salvage patients with insufficient response to PDE5 inhibitors after cavernous nerve injury” was highlighted as the most innovative research in the “Sexual function and dysfunction”session.
March 9th - 2011
Future presentations at the AUA 2011
Pelvipharm at the AUA (American Urological Association) in Washington, DC, USA, 14 -19 may 2011.
Pelvipharm will present 2 Moderated posters :
Please come and see us, we will be happy to discuss our results with you and potential applications for you.
January 11th - 2011
Future presentation at the EAU 2011
Pelvipharm at the EAU (European Association of Urology) in Vienna, Austria, 18 - 22 March 2011.
Pelvipharm will present 1 Poster:
- "Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil might salvage patients with insufficient response to PDE5 inhibitors after cavernous nerve injury"
A. Oudot, D. Behr-Roussel, S. Poirier, P. Sandner, J. Bernabé, F. Giuliano.
Please come and see us, we will be happy to discuss our results with you and potential applications for you.
February 7th - 2011
Bio-Europe Spring in Milan, March 2011
Pelvipharm will be represented by Delphine Behr-Roussel at the next BIO-Europe Spring meeting in Milan, March 14-16 2011. We warmly invite you to take this opportunity to learn more about our services.
If you’d like to set up a specific meeting at any time throughout the conference, please email staffpelvipharm@pelvipharm.com and we will be happy to assist you.
January 4th - 2011
Season's Greetings from the team at PELVIPHARM
We wish for you the very best for the new year, and extend our sincerest gratitude for your interest in our preclinical services.
